Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31531972 | 1.00 | MAPT (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL3162509 | 1.00 | MAPT (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| Hydrochloric Acid SCHEMBL4078663 | 0.99 | MAPT (0.55) | MAPTALDH1A1HTTGAAHPGD | |
| Hydrochloric Acid SCHEMBL4071405 | 0.99 | MAPT (0.55) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL5536634 | 0.90 | MAPT (0.53) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL5536639 | 0.90 | MAPT (0.53) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL9530442 | 0.89 | RECQL (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL9529227 | 0.89 | RECQL (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL7366776 | 0.88 | MAPT (0.55) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL7366780 | 0.88 | MAPT (0.55) | MAPTALDH1A1HTTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143281-A | Acid gas trigger tracer slow-release gel material and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2023-12-01 | — | — | CN | claimed |
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-20090247751-A1 | PROCESS FOR THE PREPARATION OF ZALEPLON AND AN INTERMEDIATE THEREOF | PIRAMAL HEALTHCARE LIMITED (IN) | 2009-10-01 | — | — | US | claimed |
| EP-1950213-B1 | N-{3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl}-N-ethyl-acetamide hydrochloride | RICHTER GEDEON NYRT (HU) | 2009-08-05 | — | — | EP | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | claimed |
| EP-1711501-B1 | PROCESS FOR THE SYNTHESIS OF N- [3-(3-CYANOPYRAZOLO [1,5A] PYRIMIDIN-7-YL)-PHENYL] -N-ETHYL-ACETAMIDE | RICHTER GEDEON NYRT (HU) | 2009-01-14 | — | — | EP | claimed |
| EP-2004650-A2 | PROCESS FOR THE PREPARATION OF ZALEPLON AND AN INTERMEDIATE THEREOF | Piramal Healthcare Limited (IN) | 2008-12-24 | — | — | EP | claimed |
| EP-1950213-A2 | Process for the synthesis of N-[3- (3-cyanopyrazolo [1,5a] pyrimidin-7-yl) -phnyl] -N-ethyl-acetamide | Richter Gedeon Vegyészeti Gyár R.T. (HU) | 2008-07-30 | — | — | EP | claimed |
| EP-1554279-B1 | PROCESS FOR THE PREPARATION OF ZALEPLON | ZENTIVA AS (CZ) | 2007-11-28 | — | — | EP | claimed |
| WO-2007096807-A9 | PROCESS FOR THE PREPARATION OF ZALEPLON AND AN INTERMEDIATE THEREOF | NICHOLAS PIRAMAL INDIA LTD (IN) | 2007-11-22 | — | — | WO | claimed |
| EP-1406871-A4 | PROCESS FOR THE PRODUCTION OF N- 3-(3-CYANOPYRAZOLO 1,5-A] PYRIMIDIN-7-YL)PHENYL]-N-ETHYLACETAMIDE (ZALEPLON) | BIOGAL GYOGYSZERGYAR (HU) | 2005-01-26 | — | — | EP | claimed |
| EP-1430054-A2 | PURIFICATION AND CRYSTALLINE FORMS OF ZALEPLON | BIOGAL GYOGYSZERGYAR RT. (HU) | 2004-06-23 | — | — | EP | claimed |
| WO-2004037824-A1 | PROCESS FOR THE PREPARATION OF ZALEPLON | ZENTIVA, A.S. (CZ) | 2004-05-06 | — | — | WO | claimed |
| EP-1406871-A2 | PROCESS FOR THE PRODUCTION OF N- 3-(3-CYANOPYRAZOLO 1,5-A] PYRIMIDIN-7-YL)PHENYL]-N-ETHYLACETAMIDE (ZALEPLON) | BIOGAL GYOGYSZERGYAR RT. (HU) | 2004-04-14 | — | — | EP | claimed |
| US-20030130291-A1 | Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide (zaleplon) and crystalline forms of zaleplon accessible with the process | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2003-07-10 | — | — | US | claimed |
| US-20030040522-A1 | Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon) | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2003-02-27 | — | — | US | claimed |
| WO-2003011228-A2 | PURIFICATION AND CRYSTALLINE FORMS OF ZALEPLON | BIOGAL GYOGYSZERGYAR RT (HU) | 2003-02-13 | — | — | WO | claimed |
| WO-2002100828-A2 | PROCESS FOR THE PRODUCTION OF ZALEPLON | BIOGAL GYOGYSZERGYAR RT (HU) | 2002-12-19 | — | — | WO | claimed |
| US-6476223-B2 | REACTING N-(3-(3-(DIMETHYLAMINE)-OXO-2-PROPENYL)PHENYL) ACETAMIDE WITH ETHYL IODIDE IN THE PRESENCE OF SODIUM HYDRIDE IN DIMETHYLFORMAMIDE; DILUTING (N-(3-(3-(DIMETHYLAMINE)-1-OXO-2-PROPENYL)ACETAMIDE | GADOR S. A. (AR) | 2002-11-05 | — | — | US | claimed |
| US-20020072605-A1 | Method for obtaining N-[3(3-cyano-pyrazole[1,5-a]pyrimidine-7-yl)phenyl]-N-ethyl-acetamide | GADOR S.A. (AR) | 2002-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130291-A1 | Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide (zaleplon) and crystalline forms of zaleplon accessible with the process | NPEPPS, CPN1, AZI2 | MAPT 3333/4885ALDH1A1 1809/4885HTT 2686/4885 |
| US-20020072605-A1 | Method for obtaining N-[3(3-cyano-pyrazole[1,5-a]pyrimidine-7-yl)phenyl]-N-ethyl-acetamide | DPYD, IDH3A, POLL | MAPT 4232/4885ALDH1A1 126/4885HTT 1744/4885 |
| US-20090247751-A1 | PROCESS FOR THE PREPARATION OF ZALEPLON AND AN INTERMEDIATE THEREOF | SLC30A6, SLC30A7, SLC39A3 | MAPT 3251/4885ALDH1A1 419/4885HTT 3093/4885 |
| US-20030040522-A1 | Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon) | AANAT, NPEPPS, CYP51A1 | MAPT 1097/4885ALDH1A1 1576/4885HTT 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.